Valved allografts are used routinely in the repair of
|
|
- Moris Paul
- 5 years ago
- Views:
Transcription
1 Prospective Randomized Trial of Azathioprine in Cryopreserved Valved Allografts in Children Robert E. Shaddy, MD, Linda M. Lambert, BSN, Thomas C. Fuller, PhD, Tracie Profaizer, BS, Dixie D. Thompson, RN, Shawna I. Baker, RN, Karen A. Osborne, RN, and John A. Hawkins, MD Departments of Pediatrics, Surgery, and Pathology, Primary Children s Medical Center and University of Utah, Salt Lake City, Utah Background. The purpose of this study was to prospectively assess the effects of azathioprine on the humoral immune response to HLA alloantigens and allograft function in children receiving cryopreserved valved allografts. Methods. We randomized 13 children to receive azathioprine or not to receive azathioprine (controls) after receiving a cryopreserved valved allograft. Azathioprine patients received intraoperatively 4 mg/kg of azathioprine and mg/kg once daily for 3 months after operation. Panel reactive antibodies against HLA class I and class II alloantigens were measured before, 1 month, and 3 months after operation. Results. Panel reactive antibodies were not significantly different between the azathioprine and control groups before (0.0% 0% versus 1.6% 1%), 1 month (59% 17% versus 71% 12%), or 3 months (84% 15% versus 96% 1.3%) after operation. There were no differences in degree of allograft valve stenosis between azathioprine ( mm Hg, months postoperatively) and control groups ( mm Hg, months postoperatively) or allograft valve insufficiency. Conclusions. Azathioprine does not significantly decrease the immune response to HLA alloantigens or affect the function of cryopreserved valved allografts used in children to repair congenital heart defects. (Ann Thorac Surg 2001;71:43 8) 2001 by The Society of Thoracic Surgeons Accepted for publication July 10, Address reprint requests to Dr Shaddy, Cardiology, Primary Children s Medical Center, Suite 1500, 100 North Medical Dr, Salt Lake City, Utah 84113; pcrshadd@ihc.com. Valved allografts are used routinely in the repair of congenital heart defects in children. We have previously shown that implantation of a cryopreserved valved allograft, but not open heart procedure alone, induces a significant HLA antibody response in children who receive valved allografts at the time of surgical repair for congenital heart defects [1]. Other investigators have demonstrated HLA class II alloantibodies [2] and HLA antibodies specific for valved allografts in adults and children receiving valved allografts [3]. Histologic examination in rats suggests that the immune response to valved allografts may be detrimental to valve function [4, 5]. Because of this concern of alloimmune-mediated allograft damage, animal studies have explored the role of immunouppression in altering this immune response. These studies have suggested that immunosuppressive therapy may reduce the alloimmune response to valved allograft implantation in rats and dogs [6 9]. However, data on the use of immunosuppressive therapy in humans receiving valved allografts is lacking. Previous studies have demonstrated that azathioprine suppresses the HLA alloantibody response to donor-specific blood transfusions in renal allograft recipients [10]. The purpose of this study was to prospectively study the effects of azathioprine on the humoral immune response and allograft function in children receiving valved allografts at the time of operation for repair of a congenital heart defect. Material and Methods Study Patients Between July 1996 and May 1999, we prospectively randomized 20 children to receive either azathioprine or no azathioprine (controls) after receiving a cryopreserved valved allograft in the pulmonary position as part of reparative operation for a congenital heart defect. The study was approved by the Institutional Review Boards at the University of Utah Health Sciences Center (July 1996) and Primary Children s Medical Center (August 1996). Informed consent was obtained from the parent or guardian of each patient, and informed assent was obtained from children 7 years of age or older. All procedures followed were in accordance with institutional guidelines. All patients who were scheduled to receive a cryopreserved valved allograft at the time of surgical repair of a congenital heart defect were approached for enrollment. A total of 32 patients were approached for enrollment. Twelve patients refused enrollment for a variety of reasons, including the parents or the patient just did not want to be involved in the study (n 6), concern about taking azathioprine (n 2), and concern about blood draws, taking daily medications, and infection in 1 patient each. One family refused to enroll their 2001 by The Society of Thoracic Surgeons /01/$20.00 Published by Elsevier Science Inc PII S (00)
2 44 SHADDY ET AL Ann Thorac Surg AZATHIOPRINE AND VALVED ALLOGRAFTS IN CHILDREN 2001;71:43 8 infant because they were only interested in receiving azathioprine. Twenty patients were enrolled in the study. Patient diagnoses were tetralogy of Fallot (n 9), transposition of the great arteries (n 4), truncus arteriosus (n 4), and aortic valve disease (n 3). Eleven patients had undergone previous surgical repair or palliation of a congenital heart defect, but none had previously received allograft material as part of that repair. Seven patients who were initially enrolled withdrew before completion of the study. Four patients in the azathioprine group withdrew: 1 patient with tetralogy of Fallot and atrioventricular septal defect died 12 hours postoperatively because of low cardiac output; 1 patient withdrew after the 1 week blood draw because he did not want any more blood draws; 1 patient was withdrawn by the attending physician because of fever and grampositive bacteremia that was successfully and uneventfully treated with antibiotics; 1 patient was withdrawn by the attending physician because of diarrhea and Clostridium difficile colitis. Three control patients withdrew: 1 infant with critical aortic stenosis died 5 weeks postoperatively after a successful pulmonary autograft procedure, but with persistent endocardial fibroelastosis and low cardiac output; 1 patient withdrew after the 1-week blood draw because he did not want any more blood draws; 1 patient was withdrawn because of fungal sepsis and mediastinitis. Thus, 13 patients completed the study. At the time of enrollment, patients were randomized to receive either once daily azathioprine in addition to their usual care (azathioprine group) or no additional treatment (control group) for 3 months after valved allograft implantation. A member of the research team randomized patients by drawing a blank envelope from a box with either azathioprine or control written on a paper in the envelope. All of the patient s healthcare providers in addition to the patient and the patient s family knew into which group the patient was randomized. The following preoperative blood studies were obtained on all patients: cell blood count, liver function tests (alanine aminotransferase, -glutamyl transferase, aspartate aminotransferase, protein, albumin, bilirubin), HLA type, and panel reactive antibody (PRA). Those who were randomized to receive azathioprine were administered intravenously 4 mg/kg of azathioprine in the operating room within 1 hour before operation. All patients received irradiated and leukocyte-filtered blood products to prevent sensitization to allogeneic blood cells. Blood products were filtered with Purecell leukocyte reduction filters (Pall Biomedical Products Co, East Hills, NY) and irradiated with Cs-137 at 30 Gy. Study Design and Measurements Starting on the day after operation, each patient received a single daily dose of azathioprine, 1 to 2 mg/kg, intravenously (if unable to take medications by mouth) or orally (when able to take medications by mouth) to maintain a white blood cell count (WBC) of 4,000/mm 2 to 7,000/mm 2. If the WBC decreased to less than 4,000, then the dose of azathioprine was either decreased or temporarily discontinued until the WBC was more than 4,000/ mm 2. If the WBC increased significantly above 7,000/ mm 2, the azathioprine dose was increased to a maximum of 2.5 mg/kg per day to attempt to maintain the WBC between 4,000/mm 2 and 7,000/mm 2. Panel reactive antibody, liver function tests, and blood cell counts were performed at the following times after operation: 1 week, 1 month, and 3 months. In those who received azathioprine, an additional blood draw was performed at 2 months postoperatively to monitor for adverse effects. Postoperatively, all patients were monitored for evidence of infection and were treated appropriately if concerns of infection arose. At the time of routine blood draws for the study, parents and patients were asked about any adverse effects or infections since the previous blood draw. Echocardiograms were obtained using standard views in all patients at the discretion of each patient s cardiologist. HLA-A, HLA-B, and HLA-C loci serotyping was performed on all patients using the standard complementdependent cytotoxicity (CDC) test and in-house serologic reagents. Panel Reactive Antibody Panel reactive antibody was measured in two ways: (1) using an antiglobulin cytotoxicity technique (AHG-CDC) against an HLA-select frozen T-lymphocyte panel and (2) by flow cytometry using a pool of HLA class I and class II purified antigens coupled to latex beads. The AHG-CDC technique increases the sensitivity of complementdependent cytotoxicity by incorporating an antihuman light-chain immunoglobulin reagent. We used a frozen T-lymphocyte panel composed of 40 individuals of diverse HLA type and racial background [11]. Panel reactive antibody is expressed as the percentage of lymphocyte panel members against which each patient s serum reacts and therefore, reflects the breadth of allosensitization against the potential donor population. Using flow cytometry, HLA-A, HLA-B, and HLA-C (class I) and HLA DR/DQ (class II) antibodies were determined. This technique uses affinity-purified, soluble class I and class II antigens from 30 different cell lines that are coupled individually to uniform latex beads and then pooled together to create a panel that represents the majority of serologically recognized HLA class I and class II alloantigens (Flow-PRA I and II Beads, respectively; One Lambda, Canoga Park, CA). After incubation of the beads with 0.02 ml of the patient s serum, the beads were washed and stained with saturating goat antihuman IgG conjugated with fluorescein isothiocyanate. The percent fluorescent-positive beads (% PRA) was calculated by analysis on a Becton Dickinson FACScan flow cytometer (Becton Dickinson, Fullerton, CA) [12]. Statistical Analysis Data are expressed as mean SD (parametric data) or as median and range (nonparametric data). Comparisons between groups were made using either an unpaired t test (parametric data) or Mann-Whitney rank sum test (nonparametric data).
3 Ann Thorac Surg SHADDY ET AL 2001;71:43 8 AZATHIOPRINE AND VALVED ALLOGRAFTS IN CHILDREN 45 Table 1. Clinical Characteristics of Patients Characteristics Azathioprine Group Control Group No. of patients 6 7 Age (y) (median, range) 1.1 ( ) 3.2 ( ) Weight (kg) a Allograft Position Pulmonary 6 7 Type Pulmonary 5 5 Aortic 1 2 Diameter (mm) Length (cm) Cryopreservation time (mo) Donor age (y) patients in both groups demonstrated a broad, multispecific antibody pattern. Thus, azathioprine did not alter the humoral immune response to valved allografts. Echocardiography Echocardiograms obtained in patients in the azathioprine group at months after operation were compared to echocardiograms obtained in patients in the control group at months after operation. When comparing patients who received azathioprine to control patients, echocardiograms demonstrated no significant difference in the Doppler gradient across the conduit from the right ventricle to the pulmonary artery ( mm Hg versus mm Hg) (Table 2). Similarly, there were no significant differences in the degree of a Mean standard deviation. p value is not significant. Results Clinical Characteristics Thirteen patients completed the study, 6 in the azathioprine group and 7 in the control group. There were no significant differences between groups with regard to patient age or weight, or with regard to allograft type, size, or cryopreservation time, or donor age (Table 1). Eight of the children in the study were less than 2 years old. ABO blood type was available in 5 allografts used in the azathioprine group and 3 allografts used in the control group. Purely by chance, in the 5 allografts used in the azathioprine group for which ABO blood type was available, allograft blood types were identical to patient blood types in those who received the allografts. In the 3 allografts used in the control group for which ABO blood type was available, 2 allograft blood types were identical and 1 was incompatible with patient blood type. HLA typing was not available in any of the allografts. Patients who were randomized to the azathioprine group received mg/kg per day at the time of discharge from the hospital after operation. HLA Antibody There were no significant differences in the measured class I PRA between those who received azathioprine and control patients at any point during the study: before operation, and 1 week, 1 month, and 3 months after operation (Fig 1A). The two methods of measuring PRA class I, the cytotoxicity technique and the flow cytometry technique, demonstrated nearly identical results between the two methods (Fig 1B). Similarly, there were no significant differences in the class II PRA measured by flow cytometry between patients who received azathioprine and control patients at any point during the study (Fig 1C). Because of the broad panel reactivity, it was only possible to discern antibody specificity in 2 patients who showed the following specificity: B17, B5 cross-reactive group, A2, and A26, B15, B62, respectively. All other Fig 1. Humoral immune response to surgically implanted valved allografts measured before operation (Pre), and 1 week, 1 month, and 3 months after operation (Post) in patients who received azathioprine (AZA) and control patients. Humoral immune response was measured as panel reactive antibody (PRA) against (A) HLA class I alloantigens using the AHG-CDC technique (AHG-CDC PRA); (B) HLA class I alloantigens using flow cytometry (Flow I PRA); and (C) HLA class II alloantigens using flow cytometry (Flow II PRA).
4 46 SHADDY ET AL Ann Thorac Surg AZATHIOPRINE AND VALVED ALLOGRAFTS IN CHILDREN 2001;71:43 8 allograft valve insufficiency between patients who received azathioprine (3 moderate, 2 mild, 1 trace) and controls (3 moderate, 1 mild, 3 trace). One patient in the azathioprine group required replacement of his valved allograft 9 months after initial valved allograft because of significant conduit stenosis and calcification unresponsive to balloon valvuloplasty. Azathioprine Azathioprine was well tolerated. Three patients required reduction in azathioprine dosage because of mild neutropenia in 1 patient and mildly elevated transaminases in 2 patients, both of which resolved with reduction in dosage. There were no significant differences between azathioprine and control groups with regard to infection. In patients randomized to azathioprine, 1 patient had gram-positive bacteremia that required discontinuation of azathioprine and antibiotic treatment; 1 patient developed oral candidiasis and 1 patient had a streptococcal pharyngitis, both easily and successfully treated. In patients randomized to the control group, 1 patient developed fungal sepsis and mediastinitis, and 1 patient had an episode of otitis media requiring oral antibiotics. Comment This study demonstrates that azathioprine does not reduce the alloimmune HLA antibody response to valved allograft implantation in children, nor does it decrease the occurrence of allograft dysfunction. Although there was no beneficial effects from azathioprine, there also did not appear to be any significant increase in adverse effects from the use of azathioprine. The number of patients who did not complete the study was comparable between groups, as were the number of infections and deaths. It is possible that other, more potent immunosuppressants may more effectively reduce the humoral immune response to valved allografts and thus improve allograft function in these patients. However, more potent immunosuppressants have more adverse effects. Although experimental studies in animals have suggested that cyclosporine may reduce the T-cell-specific immune response to valved allografts [6 8, 9], we elected not to use cyclosporine because of its significant adverse effect profile, including susceptibility to infection, renal dysfunction, hirsuitism, and gingival hyperplasia. Instead, we elected to examine the effects of azathioprine because of its previous demonstrated efficacy in reducing allosensitization to donor-specific blood transfusions in renal transplant patients [10], the extensive decades-long experience in the prevention of rejection in solid organ transplantation in children, and its low adverse effect profile and ease of administration. We are confident that the patients received a therapeutic dose of azathioprine in this study for the following reasons. Although it is not possible to measure serum azathioprine levels, we used a dosage that has been widely used and accepted in pediatric solid organ transplantation. Furthermore, 3 patients required reduction in their azathioprine dosing during the study because of neutropenia (1 patient) and mildly Table 2. Echocardiographic Assessment of Stenosis and Insufficiency of Valved Allografts in Azathioprine Patients and Control Patients Patient Months After Operation Pulmonary Stenosis (mm Hg) Pulmonary Insufficiency Azathioprine Patients Moderate Mild Moderate Mild Trace Moderate Mean SD Control Patients Trace Mild Moderate Moderate Moderate Trace Trace Mean SD SD standard deviation. elevated serum transaminases (2 patients) that normalized after reduction in azathioprine dose. This suggests that the patients had adequate treatment with azathioprine. Thus, although reasonable doses of azathioprine were used and were well tolerated by this patient group, neither the humoral immune response to nor the function of valved allografts was significantly improved. This study confirms our previous finding that antibodies to HLA class I alloantigens are prevalent in children receiving cryopreserved valved allografts [1]. By using two independent methods for measuring HLA class I antibody, we demonstrated nearly identical class I PRA responses in both groups of patients. Furthermore, we also demonstrated the presence of HLA class II antibodies in these children using flow cytometry. Importantly, the relationship of the HLA antibody response to the histologic response of the valved allograft is unclear. Whereas some researchers have found no histologic evidence of immunologic injury to explanted valved allografts [13], other investigators have found evidence of a significant immunologic infiltration in explanted valved allografts from children [14]. Furthermore, the functional significance of any immunologic response to the allograft is even less clear. For example, Smith and colleagues [15] found no association between HLA mismatch and longterm valve function of homovital allografts. In older children, the freedom from reoperation in patients receiving valved allografts approaches 90% at 5 years in those who undergo pulmonary autograft for aortic valve disease [16 18]. However, valved allograft dysfunction continues to be a significant problem in pediatric heart surgery, particularly in small children [19, 20]. Thus, it is possible, although still speculative, that the HLA anti-
5 Ann Thorac Surg SHADDY ET AL 2001;71:43 8 AZATHIOPRINE AND VALVED ALLOGRAFTS IN CHILDREN 47 body response to valved allografts may lead to accelerated allograft dysfunction, particularly in small children. Because the majority of the children in the current study were in the high-risk age group for early allograft failure (less than 2 years of age), we can conclude that immunosuppressive therapy with azathioprine has no effect on humoral immune response to or function of valved allografts in these younger children. Continued investigation into methods of optimizing allograft function in children is warranted. To totally remove the immune response to valved allografts, it would probably require significantly stronger immunosuppressive therapy or ABO and HLA matching of allografts to recipients. Although it may be ideal to match patients and allografts with regard to ABO blood type and HLA type, it is currently impractical to do this because of the limited availability of valved allografts. The effect of ABO incompatibility on valved allograft function is unknown. Retrospective analyses of ABO incompatibility have shown this to be a risk factor for graft failure in some studies [20], but not in others [18]. In the current study, the majority of patients received an ABO-compatible valved allograft, thus lessening the impact of ABO incompatibility. Where possible, matching of ABO blood type may be worthwhile because of the presence of preexisting humoral immunity against incompatible blood group A and B antigens. It is much less clear whether attempts at more potent immunosuppressive therapy in this setting is warranted. Thus, immunosuppressive therapy with azathioprine during the first 3 months after valved allograft implantation has no effect on the humoral immune response or function of the allograft valve in the short term after implantation. This investigation was supported by Public Health Service research grant No. M01-RR00064 from the National Center for Research Resources. References 1. Shaddy RE, Hunter DD, Osborn KA, et al. Prospective analysis of HLA immunogenicity of cryopreserved valved allografts used in pediatric heart surgery. Circulation 1996; 94: Hoekstra FM, Witvliet M, Knoop CY, et al. Immunogenic human leukocyte antigen class II antigens on human cardiac valves induce specific alloantibodies. Ann Thorac Surg 1998; 66: den Hamer I, Hepkema B, Prop J, Elzenga N, Ebels T. HLA antibodies specific for cryopreserved heart valve homografts in children. J Thorac Cardiovasc Surg 1997;113: Motomura N, Imakita M, Yutani C, Kitoh Y, Kawashima Y, Oka T. Histological change in cryopreserved rat aortic allograft. J Cardiovasc Surg (Torino) 1995;36: Moustapha A, Ross DB, Bittira B, et al. Aortic valve grafts in the rat: evidence for rejection. J Thorac Cardiovasc Surg 1997;114: Schmitz-Rixen T, Megerman J, Colvin RB, Williams AM, Abbott WM. Immunosuppressive treatment of aortic allografts. J Vasc Surg 1988;7: Wagner E, Roy R, Marois Y, Douville Y, Guidoin R. Fresh venous allografts in peripheral arterial reconstruction in dogs. Effects of histocompatibility and of short-term immunosuppression with cyclosporine A and mycophenolate mofetil. J Thorac Cardiovasc Surg 1995;110: Vischjager M, Van Gulik TM, De Kleine RH, et al. Experimental arterial allografting under low and therapeutic dosages of cyclosporine for immunosuppression. Transplantation 1996;61: Yankah AC, Wottge HU, Muller-Ruchholtz W. Short-course cyclosporin A therapy for definite allograft valve survival immunosuppression in allograft valve operations. Ann Thorac Surg 1995;60:S Anderson CB, Tyler JD, Sicard GA, Anderman CK, Rodey GE, Etheredge EE. Pretreatment of renal allograft recipients with immunosuppression and donor-specific blood. Transplantation 1984;38: Fuller TC, Phelan D, Gebel HM, Rodey GE. Antigenic specificity of antibody reactive in the antiglobulinaugmented lymphocytotoxicity test. Transplantation 1982;34: Pei R, Wang G, Tarsitani C, et al. Simultaneous HLA Class I, and Class II antibodies screening with flow cytometry. Hum Immunol 1998;59: Mitchell RN, Jonas RA, Schoen FJ. Structure function correlations in cryopreserved allograft cardiac valves. Ann Thorac Surg 1995;60:S Vogt PR, Stallmach T, Niederhauser U, et al. Explanted cryopreserved allografts: a morphological and immunohistochemical comparison between arterial allografts and allograft heart valves from infants and adults. Eur J Cardiothorac Surg 1999;15: Smith JD, Hornick PI, Rasmi N, Rose ML, Yacoub MH. Effect of HLA mismatching and antibody status on homovital aortic valve homograft performance. Ann Thorac Surg 1998; 66:S Elkins RC. Pulmonary autograft: expanding indications and increasing utilizations [editorial]. J Heart Valve Dis 1994;3: Niwaya K, Knott-Craig CJ, Lane MM, Chandrasekaren K, Overholt ED, Elkins RC. Cryopreserved homograft valves in the pulmonary position: risk analysis for intermediate-term failure. J Thorac Cardiovasc Surg 1999;117: Shaddy RE, Tani LY, Sturtevant JE, Lambert LM, McGough EC. Effects of homograft blood type and anatomic type on stenosis, regurgitation and calcium in homografts in the pulmonary position. Am J Cardiol 1992;70: Clarke DR, Campbell DN, Hayward AR, Bishop DA. Degeneration of aortic valve allografts in young recipients. J Thorac Cardiovasc Surg 1993;105: Yankah AC, Alexi-Meskhishvili V, Weng Y, Schorn K, Lange PE, Hetzer R. Accelerated degeneration of allografts in the first two years of life. Ann Thorac Surg 1995;60:S71 6. INVITED COMMENTARY This study by Shaddy and colleagues from Primary Children s Medical Center in Salt Lake City is extraordinarily interesting and despite the low number of patients involved is a significant contribution to the evolving literature on immunology of cryopreserved homograft valve conduit transplants. The first point of interest is 2001 by The Society of Thoracic Surgeons /01/$20.00 Published by Elsevier Science Inc PII S (00)
Clinical Performance of Decellularized Cryopreserved Valved Allografts Compared With Standard Allografts in the Right Ventricular Outflow Tract
Clinical Performance of Decellularized Cryopreserved Valved Allografts Compared With Standard Allografts in the Right Ventricular Outflow Tract Phillip T. Burch, MD, Aditya K. Kaza, MD, Linda M. Lambert,
More informationImmunogenic Human Leukocyte Antigen Class II Antigens on Human Cardiac Valves Induce Specific Alloantibodies
Immunogenic Human Leukocyte Antigen Class II Antigens on Human Cardiac Valves Induce Specific Alloantibodies Franciska M. E. Hoekstra, MD, Marian Witvliet, BSc, Christiaan Y. Knoop, BSc, Claes Wassenaar,
More informationThe Role Of Decellularized Valve Prostheses In The Young Patient
The Role Of Decellularized Valve Prostheses In The Young Patient Francisco Diniz Affonso da Costa Human Tissue Bank PUCPR - Brazil Disclosures Ownership and patent license of the SDS decellularization
More informationCARDIOVASCULAR SURGERY
Volume 107, Number 4 April 1994 The Journal of THORACIC AND CARDIOVASCULAR SURGERY Cardiac and Pulmonary Transplantation Risk factors for graft failure associated with pulmonary hypertension after pediatric
More informationAIIograft reconstruction of the right ventricular outflow tract
Eur J Cardio-thorac Surg (1996) 10:609-615 Springer-Verlag 1996 T. P. Willems A. J. J. C. Bogers A. H. Cromme-Dijkhuis E. W. Steyerberg L. A. van Herwerden R. B. Hokken J. Hess E. Bos Received: 17 October
More informationPORCINE VALVES ARE REENDOTHELIALIZED BY HUMAN RECIPIENT ENDOTHELIUM IN VIVO
PORCINE VALVES ARE REENDOTHELIALIZED BY HUMAN RECIPIENT ENDOTHELIUM IN VIVO The degeneration of human allogeneic and porcine xenogeneic heart valves has not been clearly understood. The question is whether
More informationAortic Root Replacement Using an Allograft for Active Infective Endocarditis With Periannular Abscess: Single Center Experience
J Cardiol 2004 Jun; 436: 267 271 : Aortic Root Replacement Using an Allograft for Active Infective Endocarditis With Periannular Abscess: Single Center Experience Kazuhito Shunei Shinichi Noboru Sakiko
More informationDonor-Specific HLA Class I and CREG Antibodies in Complement-Dependent Cytotoxicity-Negative Renal Transplants
Available online at www.annclinlabsci.org 330 Annals of Clinical & Laboratory Science, vol. 40, no. 4, 2010 Donor-Specific HLA Class I and CREG Antibodies in Complement-Dependent Cytotoxicity-Negative
More informationEvaluation of Two New Antibody Detection Techniques in Kidney Transplantation. Doctoral Thesis. Dr. Petra Gombos
Evaluation of Two New Antibody Detection Techniques in Kidney Transplantation Doctoral Thesis Dr. Petra Gombos Semmelweis University Doctoral School of Pathology Supervisor: Dr. Róbert Langer, Ph.D. Consultant:
More informationThe Fate of Small-Diameter Homografts in the Pulmonary Position
The Fate of Small-Diameter Homografts in the Pulmonary Position Nicodème Sinzobahamvya, MD, Jutta Wetter, MD, Hedwig C. Blaschczok, MD, Mi-Young Cho, MD, Anne Marie Brecher, MD, and Andreas E. Urban, MD
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationResearch Presentation June 23, Nimish Muni Resident Internal Medicine
Research Presentation June 23, 2009 Nimish Muni Resident Internal Medicine Research Question In adult patients with repaired Tetralogy of Fallot, how does Echocardiography compare to MRI in evaluating
More informationThe Ross Procedure: Outcomes at 20 Years
The Ross Procedure: Outcomes at 20 Years Tirone David Carolyn David Anna Woo Cedric Manlhiot University of Toronto Conflict of Interest None The Ross Procedure 1990 to 2004 212 patients: 66% 34% Mean age:
More informationTransplantation. Immunology Unit College of Medicine King Saud University
Transplantation Immunology Unit College of Medicine King Saud University Objectives To understand the diversity among human leukocyte antigens (HLA) or major histocompatibility complex (MHC) To know the
More informationThe need for right ventricular outflow tract reconstruction
Polytetrafluoroethylene Bicuspid Pulmonary Valve Implantation James A. Quintessenza, MD The need for right ventricular outflow tract reconstruction and pulmonary valve replacement is increasing for many
More informationPost-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies
Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies Lorita M Rebellato, Ph.D., D (ABHI) Associate Professor Department of Pathology The Brody School of Medicine at ECU Scientific
More informationS. Bruce Greenberg, MD FNASCI and President, NASCI Professor of Radiology and Pediatrics University of Arkansas for Medical Sciences
S. Bruce Greenberg, MD FNASCI and President, NASCI Professor of Radiology and Pediatrics University of Arkansas for Medical Sciences No financial disclosures Aorta Congenital aortic stenosis/insufficiency
More informationCDA Position on Antibiotic Prophylaxis for Dental Patients at Risk
Antibiotic Prophylaxis for Dental Patients at Risk Certain categories of invasive dental treatment are known to produce significant bacteremias. Such bacteremias, although transient, may be detrimental
More informationThe pulmonary valve is the most common heart valve
Biologic versus Mechanical Valve Replacement of the Pulmonary Valve After Multiple Reconstructions of the RVOT Tract S. Adil Husain, MD, and John Brown, MD Indiana University School of Medicine, Department
More informationRight ventricular outflow tract reconstruction with bicuspid valved polytetrafluoroethylene conduit.
Carnegie Mellon University Research Showcase @ CMU Department of Biomedical Engineering Carnegie Institute of Technology 4-1-2011 Right ventricular outflow tract reconstruction with bicuspid valved polytetrafluoroethylene
More informationWill we face a big problem with the aortic valve/root after ASO?
Will we face a big problem with the aortic valve/root after ASO? Laurence Iserin Unité médico-chirurgicale de Cardiologie Congénitale Adulte Hôpital Universitaire Européen Georges Pompidou APHP, Université
More informationIntroduction. Study Design. Background. Operative Procedure-I
Risk Factors for Mortality After the Norwood Procedure Using Right Ventricle to Pulmonary Artery Shunt Ann Thorac Surg 2009;87:178 86 86 Addressor: R1 胡祐寧 2009/3/4 AM7:30 SICU 討論室 Introduction Hypoplastic
More informationThe Ross Operation in Children: Effects of Aortic Annuloplasty
The Ross Operation in Children: Effects of Aortic Annuloplasty Robert D. Stewart, MD, MPH, Carl L. Backer, MD, Neal D. Hillman, MD, Cynthia Lundt, MD, and Constantine Mavroudis, MD Division of Cardiovascular
More informationDecellularization of Aortic Homografts: South American and European Current Experience
Department of Cardiac Surgery Instituto de Neurologia e Cardiologia de Curitiba (INC-Cardio) Decellularization of Aortic Homografts: South American and European Current Experience Francisco Diniz Affonso
More informationThe incidence and risk factors of arrhythmias in the early period after cardiac surgery in pediatric patients
The Turkish Journal of Pediatrics 2008; 50: 549-553 Original The incidence and risk factors of arrhythmias in the early period after cardiac surgery in pediatric patients Selman Vefa Yıldırım 1, Kürşad
More informationH. Sonali Magdo 1 Kurt R. Schumacher 2 Sunkyung Yu 2 Robert J. Gajarski 3 Joshua M. Friedland-Little 4. Abstract 1 INTRODUCTION ORIGINAL ARTICLE
Accepted: March 17 DOI:.1111/petr.12938 ORIGINAL ARTICLE Clinical significance of anti- HLA antibodies associated with ventricular assist device use in pediatric patients: A United Network for Organ Sharing
More informationA Unique Milieu for Perioperative Care of Adult Congenital Heart Disease Patients at a Single Institution
Original Article A Unique Milieu for Perioperative Care of Adult Congenital Heart Disease Patients at a Single Institution Ghassan Baslaim, MD, and Jill Bashore, RN Purpose: Adult patients with congenital
More informationMajor Infection After Pediatric Cardiac Surgery: External Validation of Risk Estimation Model
Major Infection After Pediatric Cardiac Surgery: External Validation of Risk Estimation Model Andrzej Kansy, MD, PhD, Jeffrey P. Jacobs, MD, PhD, Andrzej Pastuszko, MD, PhD, Małgorzata Mirkowicz-Małek,
More informationTranscatheter Pulmonary Valve Replacement Update on progress and outcomes
Transcatheter Pulmonary Valve Replacement Update on progress and outcomes Barry Love, MD Director, Congenital Cardiac Catheterization Laboratory Mount Sinai Medical Center New York, New York Transcatheter
More informationUpdate to the Human Leukocyte Antigens (HLA) Equivalency Tables
Update to the Human Leukocyte s (HLA) Equivalency Tables Sponsoring Committee: Histocompatibility Policy/Bylaws Affected: Policy 2.11.A: Required Information for Deceased Kidney Donors, Policy 2.11.B:
More informationSerum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant
SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was
More informationClinical material and methods. Copyright by ICR Publishers 2003
Fourteen Years Experience with the CarboMedics Valve in Young Adults with Aortic Valve Disease Jan Aagaard 1, Jens Tingleff 2, Per V. Andersen 1, Christel N. Hansen 2 1 Department of Cardio-Thoracic and
More informationRepair or Replacement
Surgical intervention post MitraClip Device: Repair or Replacement Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationAccepted Manuscript. Composite PTFE-homograft with external stent as valved pulmonary conduit: All hat and no cattle? David Bichell, M.D.
Accepted Manuscript Composite PTFE-homograft with external stent as valved pulmonary conduit: All hat and no cattle? David Bichell, M.D. PII: S0022-5223(18)32653-9 DOI: 10.1016/j.jtcvs.2018.09.109 Reference:
More informationEffects of HLA-Matched Blood Transfusion for Patients Awaiting Renal Transplantation
CLINICAL AND TRANSLATIONAL RESEARCH Effects of HLA-Matched Blood Transfusion for Patients Awaiting Renal Transplantation Bernadette A. Magee, 1,4 Jeanie Martin, 1 Miceal P. Cole, 1 Kieran G. Morris, 2
More informationManagement of complex CHD in adults
Management of complex CHD in adults Victor Tsang Society of Thoracic Surgeons of Thailand 2016 The impact of infant cardiac surgery Over 90 % of infants born with CHD will reach adulthood By 2010, adults
More informationTransplant Applications of Solid phase Immunoassays Anti HLA antibody testing in solid organ transplantation
AACC Professional Course BETH ISRAEL DEACONESS MEDICAL CENTER HARVARD MEDICAL SCHOOL Transplant Applications of Solid phase Immunoassays Anti HLA antibody testing in solid organ transplantation J. Ryan
More informationIs it safe to transplant against HLA DSA in cardiothoracic patients? development and implementation of national Guidelines
Is it safe to transplant against HLA DSA in cardiothoracic patients? development and implementation of national Guidelines Dr Martin Howell. Laboratory Director. Department of H&I, NHS Blood and Transplant,
More informationBlood Components & Indications for Transfusion. Neda Kalhor
Blood Components & Indications for Transfusion Neda Kalhor Blood products Cellular Components: Red blood cells - Leukocyte-reduced RBCs - Washed RBCs - Irradiated RBCs Platelets - Random-donor platelets
More informationPediatric Echocardiography Examination Content Outline
Pediatric Echocardiography Examination Content Outline (Outline Summary) # Domain Subdomain Percentage 1 Anatomy and Physiology Normal Anatomy and Physiology 10% 2 Abnormal Pathology and Pathophysiology
More informationBasel - 6 September J.-M. Tiercy National Reference Laboratory for Histocompatibility (LNRH) University Hospital Geneva
Basel - 6 eptember 2012 J.-M. Tiercy National Reference Laboratory for Histocompatibility (LNRH) University Hospital Geneva Outline the HLA system is (a) complex anti-hla immunisation and alloreactivity
More informationThis study is currently recruiting participants.
A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation This study is currently recruiting
More informationRecent technical advances and increasing experience
Pediatric Open Heart Operations Without Diagnostic Cardiac Catheterization Jean-Pierre Pfammatter, MD, Pascal A. Berdat, MD, Thierry P. Carrel, MD, and Franco P. Stocker, MD Division of Pediatric Cardiology,
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationTransfusion Reactions. Directed by M-azad March 2012
Transfusion Reactions Directed by M-azad March 2012 Transfusion Reactions are Adverse reactions associated with the transfusion of blood and its components Transfusion reactions Non-threatening to fatal
More informationSurgical Indications of Infective Endocarditis in Children
2016 Annual Spring Scientific Conference of the KSC April 15-16, 2016 Surgical Indications of Infective Endocarditis in Children Cheul Lee, MD Pediatric and Congenital Cardiac Surgery Seoul St. Mary s
More informationDIAGNOSIS, MANAGEMENT AND OUTCOME OF HEART DISEASE IN SUDANESE PATIENTS
434 E AST AFRICAN MEDICAL JOURNAL September 2007 East African Medical Journal Vol. 84 No. 9 September 2007 DIAGNOSIS, MANAGEMENT AND OUTCOME OF CONGENITAL HEART DISEASE IN SUDANESE PATIENTS K.M.A. Sulafa,
More informationAortic valve repair is a technique that is gaining popularity
Aortic Valve Repair in Children, Including Pericardial Patch Reconstruction Aditya K. Kaza, MD,* and John A. Hawkins, MD Aortic valve repair is a technique that is gaining popularity in children because
More informationOutcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease
Outcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease TIRONE E. DAVID, MD ; SEMIN THORAC CARDIOVASC SURG 19:116-120c 2007 ELSEVIER INC. PRESENTED BY INTERN 許士盟 Mitral valve
More informationEven in this era of efficient immunosuppression, a positive
OVERVIEW Enhanced Kidney Allocation to Highly Sensitized Patients by the Acceptable Mismatch Program Frans H. J. Claas, 1 Axel Rahmel, 2 and IIias I. N. Doxiadis 1 Even in this era of efficient immunosuppression,
More informationImmunology. Anas Abu-Humaidan M.D. Ph.D. Transplant immunology+ Secondary immune deficiency
Immunology Anas Abu-Humaidan M.D. Ph.D. Transplant immunology+ Secondary immune deficiency Transplant Immunology Transplantation is the process of moving cells, tissues or organs from one site to another
More informationBicuspid aortic root spared during ascending aorta surgery: an update of long-term results
Short Communication Bicuspid aortic root spared during ascending aorta surgery: an update of long-term results Marco Russo, Guglielmo Saitto, Paolo Nardi, Fabio Bertoldo, Carlo Bassano, Antonio Scafuri,
More informationWhy so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation
Why so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation Stephen J Tomlanovich MD Objectives of this Talk Define the sensitized patient Describe the scope of the problem for a
More informationLong-term results (22 years) of the Ross Operation a single institutional experience
Long-term results (22 years) of the Ross Operation a single institutional experience Authors: Costa FDA, Schnorr GM, Veloso M,Calixto A, Colatusso D, Balbi EM, Torres R, Ferreira ADA, Colatusso C Department
More informationMitral Valve Disease, When to Intervene
Mitral Valve Disease, When to Intervene Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Current ACC/AHA guideline Stages
More informationA FUTURE WITHOUT RE-OPERATIONS?
A FUTURE WITHOUT RE-OPERATIONS? New horizons in pulmonary heart valve therapy January 29, 2018 Prof. Dr. Gerardus Bennink Chief and head of pediatric cardio-thoracic congenital surgery Heart Center of
More informationCardiac Radiology In-Training Test Questions for Diagnostic Radiology Residents
Cardiac Radiology In-Training Test Questions for Diagnostic Radiology Residents March, 2013 Sponsored by: Commission on Education Committee on Residency Training in Diagnostic Radiology 2013 by American
More informationPulmonary Valve Replacement
Pulmonary Valve Replacement with Fascia Lata J. C. R. Lincoln, F.R.C.S., M. Geens, M.D., M. Schottenfeld, M.D., and D. N. Ross, F.R.C.S. ABSTRACT The purpose of this paper is to describe a technique of
More information1. Discuss the basic pathophysiology of end-stage liver and kidney failure.
TRANSPLANT SURGERY ROTATION (PGY1, 2) A. Medical Knowledge Goal: The resident will achieve a detailed knowledge of the evaluation and treatment of a variety of disease processes. The resident will be exposed
More informationSINCE the introduction of Imuran and
Cadaveric Renal Transplantation With Cyclosporin-A and Steroids T. R. Hakala, T. E. Starzl, J. T. Rosenthal, B. Shaw, and S. watsuki SNCE the introduction of muran and prednisone in 1961, and despite the
More informationSemilunar Valve Switch Procedure: Autotransplantation of the Native Aortic Valve to the Pulmonary Position in the Ross Procedure
Semilunar Valve Switch Procedure: Autotransplantation of the Native Aortic Valve to the Pulmonary Position in the Ross Procedure Patrick T. Roughneen, FRCS, Serafin Y. DeLeon, MD, Benjamin W. Eidem, MD,
More information42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim
42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim Current Guideline for AR s/p TOF Surgery is reasonable in adults with prior repair of
More informationPredicting HLA Class II Alloantigen Immunogenicity From the Number and Physiochemical Properties of Amino Acid Polymorphisms
CLINICAL AND TRANSLATIONAL RESEARCH Predicting HLA Class II Alloantigen Immunogenicity From the Number and Physiochemical Properties of Amino Acid Polymorphisms Vasilis Kosmoliaptsis, 1,2,6 Linda D. Sharples,
More informationAtrioventricular valve repair: The limits of operability
Atrioventricular valve repair: The limits of operability Francis Fynn-Thompson, MD Co-Director, Center for Airway Disorders Surgical Director, Pediatric Mechanical Support Program Surgical Director, Heart
More informationCongenital pulmonary vein (PV) stenosis with anatomically
Pulmonary Vein Stenosis With Normal Connection: Associated Cardiac Abnormalities and Variable Outcome John P. Breinholt, BS, John A. Hawkins, MD, LuAnn Minich, MD, Lloyd Y. Tani, MD, Garth S. Orsmond,
More informationShould red cells be matched for transfusions to patients listed for renal transplantation?
Should red cells be matched for transfusions to patients listed for renal transplantation? Dr M.Willicombe Imperial College Renal and Transplant Centre, Hammersmith Hospital Should red cells be matched
More informationDeok Young Choi, Gil Hospital, Gachon University NEONATES WITH EBSTEIN S ANOMALY: PROBLEMS AND SOLUTION
Deok Young Choi, Gil Hospital, Gachon University NEONATES WITH EBSTEIN S ANOMALY: PROBLEMS AND SOLUTION Carpentier classification Chauvaud S, Carpentier A. Multimedia Manual of Cardiothoracic Surgery 2007
More informationAntibody-Mediated Rejection in the Lung Allograft. Gerald J Berry, MD Dept of Pathology Stanford University Stanford, CA 94305
Antibody-Mediated Rejection in the Lung Allograft Gerald J Berry, MD Dept of Pathology Stanford University Stanford, CA 94305 Gerald J Berry, MD Professor of Pathology Stanford University, Stanford, CA
More informationExpanding Candidate and Deceased Donor HLA Typing Requirements to Provide Greater Consistency Across Organ Types
At-a-Glance Expanding Candidate and Deceased Donor HLA Typing Requirements to Provide Greater Consistency Across Organ Types Affected/Proposed Policy: 2.8.A (Required Information for Deceased Kidney Donors);
More informationAPHERESIS FOR DESENSITIZATION OF NON-RENAL TRANSPLANTS
APHERESIS FOR DESENSITIZATION OF NON-RENAL TRANSPLANTS GOW AREPALLY, MD MEDICAL DIRECTOR DUKE THERAPEUTIC APHERESIS SERVICE ASSOCIATE PROFESSOR, MEDICINE AMERICAN SOCIETY FOR APHERESIS MAY 25 TH 2013 OVERVIEW
More informationSince first successfully performed by Jatene et al, the
Long-Term Predictors of Aortic Root Dilation and Aortic Regurgitation After Arterial Switch Operation Marcy L. Schwartz, MD; Kimberlee Gauvreau, ScD; Pedro del Nido, MD; John E. Mayer, MD; Steven D. Colan,
More informationThe Journal of Thoracic and Cardiovascular Surgery
Accepted Manuscript Dream Big in Every Small Step Lok Sinha, MD, Can Yerebakan, MD PII: S0022-5223(19)30013-3 DOI: https://doi.org/10.1016/j.jtcvs.2018.12.086 Reference: YMTC 13988 To appear in: The Journal
More informationThe clinical problem of atrioventricular valve regurgitation
Mitral Regurgitation in Congenital Heart Defects: Surgical Techniques for Reconstruction Richard G. Ohye Mitral valve regurgitation (MR) is an important source of morbidity and mortality worldwide. While
More informationManagement of a Patient after the Bidirectional Glenn
Management of a Patient after the Bidirectional Glenn Melissa B. Jones MSN, APRN, CPNP-AC CICU Nurse Practitioner Children s National Health System Washington, DC No Disclosures Objectives qbriefly describe
More informationMODERATOR Felix Rapaport, other members of this
The First Lung Transplant in Man (1963) and the First Heart Transplant in Man (1964) J.D. Hardy MODERATOR Felix Rapaport, other members of this distinguished panel, and members of the audience, I will
More informationInter mediate-ter m Results of Repair of Congenital Heart Diseases Using Pulmonary Homografts
HK J Paediatr (new series) 2005;10:271-281 Inter mediate-ter m Results of Repair of Congenital Heart Diseases Using Pulmonary Homografts KS LUN, CSW CHIU, TC YUNG, YF CHEUNG, LC CHENG, AKT CHAU Abstract
More informationClinical Study Different Impact of Pretransplant Anti-HLA Antibodies Detected by Luminex in Highly Sensitized Renal Transplanted Patients
BioMed Research International Volume 2013, Article ID 738404, 5 pages http://dx.doi.org/10.1155/2013/738404 Clinical Study Different Impact of Pretransplant Anti-HLA Antibodies Detected by Luminex in Highly
More informationCopyright information:
Posttransplant reduction in preexisting donor-specific antibody levels after belataceptversus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT Robert A Bray, Emory University
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More information- Transplantation: removing an organ from donor and gives it to a recipient. - Graft: transplanted organ.
Immunology Lecture num. (21) Transplantation - Transplantation: removing an organ from donor and gives it to a recipient. - Graft: transplanted organ. Types of Graft (4 types): Auto Graft - From a person
More informationMid-term Result of One and One Half Ventricular Repair in a Patient with Pulmonary Atresia and Intact Ventricular Septum
Mid-term Result of One and One Half Ventricular Repair in a Patient with Pulmonary Atresia and Intact Ventricular Septum Kagami MIYAJI, MD, Akira FURUSE, MD, Toshiya OHTSUKA, MD, and Motoaki KAWAUCHI,
More informationDetection of HLA Class I-Specific Antibodies by the QuikScreen Enzyme-Linked Immunosorbent Assay
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, May 1997, p. 252 257 Vol. 4, No. 3 1071-412X/97/$04.00 0 Copyright 1997, American Society for Microbiology Detection of HLA Class I-Specific Antibodies by
More informationOutline. Congenital Heart Disease. Special Considerations for Special Populations: Congenital Heart Disease
Special Considerations for Special Populations: Congenital Heart Disease Valerie Bosco, FNP, EdD Alison Knauth Meadows, MD, PhD University of California San Francisco Adult Congenital Heart Program Outline
More informationAntihuman leukocyte antigen (HLA) antibodies can be
Antihuman Leukocyte Antigen Specific Antibody Strength Determined by Complement-Dependent or Solid-Phase Assays Can Predict Positive Donor-Specific Crossmatches Ibrahim Batal, MD; Adriana Zeevi, PhD; John
More information2/28/2017. Adult Heart Transplants Donor and Recipient Characteristics UNOS, Retransplant VCM. Other /2015 (N = 24,474)
1 46% 2% 3% 4% 0% 2% 2% CHD HCM ICM NICM RCM 49% 3% 3% 3% 1% 3% 3% Retransplant VCM 42% Other 35% 1/1982 6/2015 1/2009 6/2015 2016 JHLT. 2016 Oct; 35(10): 1149-1205 UNOS, 2017 Adult Heart Transplants Donor
More information5.8 Congenital Heart Disease
5.8 Congenital Heart Disease Congenital heart diseases (CHD) refer to structural or functional heart diseases, which are present at birth. Some of these lesions may be discovered later. prevalence of Chd
More informationDepartment for Cardiac and Thoracic Vascular Surgery, University of Luebeck, Germany
Fifty-Two Months Mean Follow Up of Decellularized SynerGraft -Treated Pulmonary Valve Allografts J. F. Matthias Bechtel, Ulrich Stierle, Hans-Hinrich Sievers Department for Cardiac and Thoracic Vascular
More informationThe application of autologous pulmonary artery in surgical correction of complicated aortic arch anomaly
Original Article The application of autologous pulmonary artery in surgical correction of complicated aortic arch anomaly Shusheng Wen, Jianzheng Cen, Jimei Chen, Gang Xu, Biaochuan He, Yun Teng, Jian
More informationQuantifying HLA-specific antibodies in patients undergoing desensitization Andrea Zachary a and Nancy L. Reinsmoen b
Quantifying HLA-specific antibodies in patients undergoing desensitization Andrea Zachary a and Nancy L. Reinsmoen b a John Hopkins University, Immunogenetics Laboratory, Baltimore, Maryland and b Cedars-Sinai
More informationOrgan transplantation in Bulgaria
Cell Tissue Banking (28) 9:337 342 DOI 1.17/s1561-7-935-2 Organ transplantation in Bulgaria Elissaveta Naumova Æ Petar Panchev Æ Pencho J. Simeonov Æ Anastassia Mihaylova Æ Kalina Penkova Æ Petia Boneva
More informationHeart Center University of Cologne
A future without re-operations? New horizons in pulmonary heart valve therapy January 29, 2018 Prof. Dr. Gerardus Bennink Chief and head of pediatric cardio-thoracic congenital surgery Heart Center of
More informationPulmonary hypertension is a significant cause of morbidity
Randomized Controlled Study of Inhaled Nitric Oxide After Operation for Congenital Heart Disease Ronald W. Day, MD, John A. Hawkins, MD, Edwin C. McGough, MD, Kevin L. Crezeé, RRT, and Garth S. Orsmond,
More informationABO INCOMPATILIBITY AND TRANSPLANTATION
ABO INCOMPATILIBITY AND TRANSPLANTATION Aleksandar Mijovic Consultant Haematologist/Senior Lecturer King s College Hospital/NHS Blood and Transplant London, UK RTC Edu Meeting May 2017 ABO antigens Expressed
More informationAdvanced Congenital Cardiac Morphology. Sunday, Oct. 22, to Thursday, Oct. 26, Learn more: chop.cloud-cme.com
Advanced Congenital Cardiac Morphology Sunday, Oct. 22, to Thursday, Oct. 26, 2017 Ruth and Tristram Colket, Jr. Translational Research Building Learn more: chop.cloud-cme.com 1 Course Information Course
More informationPharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents
BUMC Proceedings 1999;12:110-112 Pharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents CHERYLE GURK-TURNER, RPH Department of Pharmacy Services, BUMC wo mouse/human
More informationCovered Critical Illness Conditions Appendix
Covered Critical Illness Conditions Appendix Effective Date: February 1, 2010 This Appendix contains definitions for those Conditions that are covered under the Manulife Financial Group Critical Illness
More informationXM-ONE XM-ONE XM-ONE. References XMO_V4.0_100205_CE.EU
Transplantation Cross match Transplantation Cross match XMO_V4._125_CE.EU Manufactured by: ABSORBER AB Address: Drottninggatan 33 SE-13 95 Stockholm, Sweden E-mail: info-ssp@olerup.com Tel: +46 8 5 89
More informationCarol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT
Carol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT History Why is blood transfusion involved? What tests are performed in blood transfusion and why? What does a protocol look
More informationCLINICAL GUIDELINES. Summary of Literature and Recommendations Concerning Immunization and Steroid Injections Thomas J. Gilbert M.D., M.P.P.
CLINICAL GUIDELINES Summary of Literature and Recommendations Concerning Immunization and Steroid Injections Thomas J. Gilbert M.D., M.P.P. 11/2/15 Several practices routinely delay steroid injections
More information